肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

《HR _HER2-转移性乳腺癌患者内分泌治疗和靶向治疗：ASCO更新版指南》解读

2021-10-30 武汉大学中南医院放化疗科 肿瘤综合治疗电子杂志

乳腺癌激素受体阳性妇瘤乳腺肿瘤

激素受体阳性(hormone receptor positive,HR+)乳腺癌是最常见的乳腺癌亚型。

中文标题：

《HR _HER2-转移性乳腺癌患者内分泌治疗和靶向治疗：ASCO更新版指南》解读

发布机构：

武汉大学中南医院放化疗科

发布日期：

2021-10-30

简要介绍：

激素受体阳性(hormone receptor positive,HR+)乳腺癌是最常见的乳腺癌亚型。近几年,随着各项内分泌联合靶向治疗的Ⅲ期临床研究数据的公布,HR+/人类表皮生长因子受体2阴性(human epidermal growth factor receptor 2 negative,HER2-)晚期乳腺癌的治疗模式逐步由单一内分泌治疗向内分泌联合靶向治疗的模式转变。美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)专家小组根据2016年以来的51项最新研究结果,于2021年7月29日在Journal of Clinical Oncology在线全文发表了《HR+/HER2-转移性乳腺癌患者内分泌治疗和靶向治疗:ASCO更新版指南》。本文将对其中的内容进行解读。 

相关资料下载：
[AttachmentFileName(sort=1, fileName=《HR _HER2-转移性乳腺癌患者内分泌治疗和靶向治疗：ASCO更新版指南》解读.pdf)] GetToolGuiderByIdResponse(projectId=1, id=31c261c002280a61, title=《HR _HER2-转移性乳腺癌患者内分泌治疗和靶向治疗：ASCO更新版指南》解读, enTitle=, guiderFrom=肿瘤综合治疗电子杂志, authorId=0, author=, summary=激素受体阳性(hormone receptor positive,HR+)乳腺癌是最常见的乳腺癌亚型。, cover=https://img.medsci.cn/20211130/1638257521661_5579292.png, journalId=0, articlesId=null, associationId=2194, associationName=武汉大学中南医院放化疗科, associationIntro=武汉大学中南医院放化疗科 , copyright=0, guiderPublishedTime=Sat Oct 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">激素受体阳性(hormone receptor positive,HR+)乳腺癌是最常见的乳腺癌亚型。近几年,随着各项内分泌联合靶向治疗的Ⅲ期临床研究数据的公布,HR+/人类表皮生长因子受体2阴性(human epidermal growth factor receptor 2 negative,HER2-)晚期乳腺癌的治疗模式逐步由单一内分泌治疗向内分泌联合靶向治疗的模式转变。美国临床肿瘤学会(American Society of Clinical Oncology,ASCO)专家小组根据2016年以来的51项最新研究结果,于2021年7月29日在Journal of Clinical Oncology在线全文发表了《HR+/HER2-转移性乳腺癌患者内分泌治疗和靶向治疗:ASCO更新版指南》。本文将对其中的内容进行解读。&nbsp;</span></p>, tagList=[TagDto(tagId=285, tagName=乳腺癌), TagDto(tagId=34928, tagName=激素受体阳性), TagDto(tagId=117297, tagName=妇瘤乳腺肿瘤)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=24, categoryName=胸心外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=34928, guiderKeyword=激素受体阳性, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=2196, appHits=109, showAppHits=0, pcHits=321, showPcHits=2087, likes=1, shares=16, comments=6, approvalStatus=1, publishedTime=Tue Nov 30 15:37:51 CST 2021, publishedTimeString=2021-10-30, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Tue Nov 30 15:37:30 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 10:26:32 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=《HR _HER2-转移性乳腺癌患者内分泌治疗和靶向治疗：ASCO更新版指南》解读.pdf)])
《HR _HER2-转移性乳腺癌患者内分泌治疗和靶向治疗：ASCO更新版指南》解读.pdf
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1182956, encodeId=45821182956e4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125d6164861, createdName=ms4000001034418498, createdTime=Mon Jan 10 21:15:31 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077016, encodeId=b44910e7016d1, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Dec 05 08:20:48 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075795, encodeId=f21e10e57957a, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Wed Dec 01 10:28:07 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075666, encodeId=909d10e566605, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Dec 01 06:59:25 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075460, encodeId=437710e5460a3, content=学习了，谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Nov 30 15:48:03 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2022-01-10 ms4000001034418498

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1182956, encodeId=45821182956e4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125d6164861, createdName=ms4000001034418498, createdTime=Mon Jan 10 21:15:31 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077016, encodeId=b44910e7016d1, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Dec 05 08:20:48 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075795, encodeId=f21e10e57957a, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Wed Dec 01 10:28:07 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075666, encodeId=909d10e566605, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Dec 01 06:59:25 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075460, encodeId=437710e5460a3, content=学习了，谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Nov 30 15:48:03 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2021-12-05 微探

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1182956, encodeId=45821182956e4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125d6164861, createdName=ms4000001034418498, createdTime=Mon Jan 10 21:15:31 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077016, encodeId=b44910e7016d1, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Dec 05 08:20:48 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075795, encodeId=f21e10e57957a, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Wed Dec 01 10:28:07 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075666, encodeId=909d10e566605, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Dec 01 06:59:25 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075460, encodeId=437710e5460a3, content=学习了，谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Nov 30 15:48:03 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2021-12-01 ms9000001873897494

    很实用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1182956, encodeId=45821182956e4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125d6164861, createdName=ms4000001034418498, createdTime=Mon Jan 10 21:15:31 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077016, encodeId=b44910e7016d1, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Dec 05 08:20:48 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075795, encodeId=f21e10e57957a, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Wed Dec 01 10:28:07 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075666, encodeId=909d10e566605, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Dec 01 06:59:25 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075460, encodeId=437710e5460a3, content=学习了，谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Nov 30 15:48:03 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2021-12-01 微探

    学习学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1182956, encodeId=45821182956e4, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=125d6164861, createdName=ms4000001034418498, createdTime=Mon Jan 10 21:15:31 CST 2022, time=2022-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1077016, encodeId=b44910e7016d1, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Dec 05 08:20:48 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075795, encodeId=f21e10e57957a, content=很实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b415562646, createdName=ms9000001873897494, createdTime=Wed Dec 01 10:28:07 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075666, encodeId=909d10e566605, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Wed Dec 01 06:59:25 CST 2021, time=2021-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1075460, encodeId=437710e5460a3, content=学习了，谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Nov 30 15:48:03 CST 2021, time=2021-11-30, status=1, ipAttribution=)]
    2021-11-30 1209e435m98(暂无昵称)

    学习了，谢谢分享

    0

相关指南

乳腺癌患者的营养治疗专家共识

中国抗癌协会肿瘤营养专业委员会 · 2021-08-09

FDA指导原则：pCR作为高风险早期乳腺癌新辅助治疗终点加速药物研发

美国食品和药品监督管理局(FDA,Food and Drug Administration) · 2021-10-01

中国抗癌协会乳腺癌诊治指南与规范（2021年版）

中国抗癌协会乳腺癌专业委员会(CACA-CBCS,Chinese Anti-Cancer Association, Committee of Breast Cancer Society) · 2021-08-30

2021 SITC临床实践指南：乳腺癌的免疫治疗

肿瘤免疫治疗学会(SITC,Society for Immunotherapy of Cancer) · 2021-08-09

乳腺癌内分泌辅助治疗相关子宫内膜病变管理指南（2021年版）

中国抗癌协会(Chinese Anti-cancer Association) · 2021-08-02

乳腺癌患者的药学门诊管理专家共识

广东省药学会 · 2021-07-16

拓展阅读

2016ASCO：激素受体阳性的转移性乳腺癌的内分泌治疗指南

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2016-05-27

2018 AIOM建议：绝经前激素受体阳性的早期乳腺癌患者辅助内分泌治疗

意大利肿瘤医学协会(AIOM,Italian Association of Medical Oncology) · 2018-06-07

第6届晚期乳腺癌国际共识会议激素受体阳性晚期乳腺癌更新要点及解读

海军军医大学附属长海医院甲状腺乳腺外科 · 2022-04-16